BEAM
Beam Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 3
Stock Price Surged Significantly
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Revenue Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BEAM
Beam Therapeutics Inc.
A company that developing DNA base editing and gene editing technologies
238 Main Street, Cambridge, MA 02142
--
Founded on January 25, 2017, Beam Therapeutics Inc., is a biotechnology company dedicated to creating a new class of precision genetic medicines based on its proprietary base editing technology, with the vision of providing lifelong treatment for patients suffering from serious diseases.
Company Financials
EPS
BEAM has released its 2025 Q3 earnings. EPS was reported at -1.1, versus the expected -1.03, missing expectations. The chart below visualizes how BEAM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BEAM has released its 2025 Q3 earnings report, with revenue of 9.70M, reflecting a YoY change of -32.03%, and net profit of -112.73M, showing a YoY change of -16.61%. The Sankey diagram below clearly presents BEAM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
